Skip to main content

Research

New
History

Explore

Search
Cases
Professionals

Resources

Blog
Pricing
Docs

Sign in Create account

Cases

CourtFilingsPetition dateMore filters

Case

Funded debt

Stage

Exit

Next hearing

Last activity

Petition date

Court

KaloBios Pharmaceuticals, Inc. Professionals

KaloBios Pharmaceuticals, Inc.

Chapter 7 · Sale Process

Case No. 15-12628·Delaware·Petition date Dec 29, 2015

Research this case Track this case Sign in

OverviewProfessionals

Professionals

Retained professionals and compensation participants, joined to their source filings.

B

Batuta Capital Advisors LLC

Retained · fee applicantFinancial Advisor · Debtor

Dkt. 97

H

Hogan Lovells US LLP

Fee applicant

H

Horne LLP

RetainedAccounting / Auditor · Debtor

Dkt. 457

M

Morris, Nichols, Arsht & Tunnell LLP

Fee applicant

P

Pirinate Consulting Group, LLC

RetainedChief Restructuring Officer · Debtor

Dkt. 77

P

Prime Clerk LLC

Fee applicant

Judge: Laurie Selber Silverstein
Petition assets: $500K–$1M
Petition liabilities: $1M–$10M
Industry: Healthcare

KaloBios Pharmaceuticals, Inc. is a San Francisco-based clinical-stage biopharmaceutical company developing Humaneered® monoclonal antibody therapies for cancer patients. Its pipeline centers on two investigational antibodies: lenzilumab (KB003), an anti-GM-CSF Humaneered® mAb targeting chronic myelomonocytic leukemia, and KB004, an anti-EphA3 Humaneered® mAb targeting hematologic malignancies and solid tumors. Formerly NASDAQ-listed under ticker KBIO, KaloBios employed approximately 20 people prior to a November 2015 workforce reduction that eliminated roughly 61% of its staff.

Case background, summaries, and key terms are generated from the filings on this docket. Docket entries and documents come from the court.

Report a data error